# Aurenar

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aurenar

- Industry: Medical Devices & Equipment
- Headquarters: Saint Louis, US
- Website: www.aurenar.com/
- Total disclosed funding: $5.7M
- Latest round: Seed (Jun 30, 2026)
- Investors on record: 4

## About

Based in the US, Aurenar, Inc is a neurotechnology company dedicated to developing innovative solutions that enhance patient care in intensive care settings through advanced neuromodulation techniques. Founded in 2023 in Saint Louis, US, Aurenar, Inc., founded by Dr. Eric Leuthardt (CEO), Dr. Anna Huguenard (CTO), Anna Huguenard and Jeff Dunn focuses on neurotechnology aimed at treating inflammation through a unique ear-worn device. In June 2026, Aurenar, Inc. raised USD 5.7 million in seed funding co-led by American Heart Association and Solas BioVentures, with participation from BJC Health and Kaleida Capital. Aurenar, Inc specializes in innovative neurotechnology designed to address inflammation, a critical factor in complications and costs within Intensive Care Units (ICUs). Their core product is an ear-worn device that utilizes imperceptible and non-invasive stimulation to activate a nerve located in the ear, enhancing the body’s natural control of inflammation. This device aims to improve patient outcomes and reduce hospital lengths of stay, ultimately lowering the cost of care for high-cost patients in critical settings. The primary beneficiaries of Aurenar’s offerings include healthcare providers in the ICU environment, with potential applications extending to hospitals and specialized medical institutions across North America and Europe, where high-volume, high-cost patient care is prevalent. Aurenar’s revenue model is structured around transactions with healthcare institutions and providers who integrate their wearable neurostimulation device into patient care protocols. These transactions may occur through direct sales to hospitals or partnerships with medical device distributors, facilitating broader access to their technology. The company emphasizes the value proposition of its flagship product, which is positioned to deliver significant cost savings and improved clinical outcomes, thus making it an attractive offering for healthcare systems facing financial pressures. The pricing structure is designed to reflect the operational benefits derived from its implementation, aligning with the financial objectives of healthcare providers seeking to optimize resource utilization and enhance patient care. In June 2026, Aurenar, Inc raised USD 5.7 mn in Seed funding aimed at advancing their V-Link neuromodulation platform. The funding will facilitate pivotal trials, including final device development, verification and validation testing, and necessary regulatory submissions to the U.S. Food and Drug Administration. Aurenar plans to expand its product offerings and market presence, particularly targeting healthcare institutions across North America and Europe, where demand for innovative solutions in patient care is high.

## Funding rounds

- Seed, Jun 30, 2026, $5.7M — Solas BioVentures, American Heart Association, Kaleida Capital, BJC Health System

## Investors

- Solas BioVentures (https://capitalatlas.ai/funds/solas-bioventures) — Seed
- American Heart Association — Seed
- Kaleida Capital (https://capitalatlas.ai/funds/kaleida-capital) — Seed
- BJC Health System — Seed